1. Home
  2. TBPH vs ARQQ Comparison

TBPH vs ARQQ Comparison

Compare TBPH & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • ARQQ
  • Stock Information
  • Founded
  • TBPH 2013
  • ARQQ 2017
  • Country
  • TBPH United States
  • ARQQ United Kingdom
  • Employees
  • TBPH N/A
  • ARQQ N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • ARQQ Computer Software: Prepackaged Software
  • Sector
  • TBPH Health Care
  • ARQQ Technology
  • Exchange
  • TBPH Nasdaq
  • ARQQ Nasdaq
  • Market Cap
  • TBPH 699.0M
  • ARQQ 622.8M
  • IPO Year
  • TBPH N/A
  • ARQQ N/A
  • Fundamental
  • Price
  • TBPH $14.75
  • ARQQ $36.00
  • Analyst Decision
  • TBPH Strong Buy
  • ARQQ Strong Buy
  • Analyst Count
  • TBPH 4
  • ARQQ 1
  • Target Price
  • TBPH $23.00
  • ARQQ $60.00
  • AVG Volume (30 Days)
  • TBPH 284.3K
  • ARQQ 962.4K
  • Earning Date
  • TBPH 11-10-2025
  • ARQQ 12-04-2025
  • Dividend Yield
  • TBPH N/A
  • ARQQ N/A
  • EPS Growth
  • TBPH N/A
  • ARQQ N/A
  • EPS
  • TBPH 0.26
  • ARQQ 0.48
  • Revenue
  • TBPH $77,205,000.00
  • ARQQ $241,000.00
  • Revenue This Year
  • TBPH $79.82
  • ARQQ $86.94
  • Revenue Next Year
  • TBPH N/A
  • ARQQ $1,017.32
  • P/E Ratio
  • TBPH $59.49
  • ARQQ $87.36
  • Revenue Growth
  • TBPH 24.49
  • ARQQ N/A
  • 52 Week Low
  • TBPH $7.90
  • ARQQ $5.22
  • 52 Week High
  • TBPH $15.34
  • ARQQ $62.00
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 58.51
  • ARQQ 42.15
  • Support Level
  • TBPH $14.11
  • ARQQ $41.50
  • Resistance Level
  • TBPH $15.34
  • ARQQ $46.01
  • Average True Range (ATR)
  • TBPH 0.42
  • ARQQ 4.96
  • MACD
  • TBPH 0.06
  • ARQQ -1.01
  • Stochastic Oscillator
  • TBPH 63.55
  • ARQQ 12.01

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About ARQQ Arqit Quantum Inc.

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.

Share on Social Networks: